ZolpiMistTM: A new formulation of zolpidem tartrate for the short-term treatment of insomnia in the US

Nature and Science of Sleep

Volumn 2, Issue , 2010, Pages 79-84

  Neubauer, David N ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Hypnotic; Insomnia; Oral spray formulation; Zolpidem; ZolpiMist

Indexed keywords

EID: 80053893294     PISSN: None     EISSN: 11791608     Source Type: Journal    
DOI: 10.2147/nss.s6431     Document Type: Review

References (17)

1. American Academy of Sleep Medicine. The International Classification of Sleep Disorders: Diagnostic and Coding Manual, ICSD-2. 2nd ed. Westchester, IL: American Academy of Sleep Medicine; 2005.
2. National Institutes of Health. National Institutes of Health state of the science conference statement on manifestations and management of chronic insomnia in adults, 2005 June 13-15. Sleep. 2005;28(9): 1049-1057.
3. Buysse DJ. Chronic insomnia. Am J Psychiatry. 2008;165(6): 678-686.
4. Mohler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002;300(1):2-8. (Pubitemid 34028501)
5. NovaDel Pharma Inc. NovaDel Pharma initiates human study of lingual spray version of world's leading sleep agent. [press release] 2004 December 7. media.integratir.com/nvd/PressReleases/120704-NovaDel%20News.pdf. Accessed 2009 Dec 12.
6. US Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: Applications covered by section 505(b)(2);1999.
7. NovaDel Pharma Inc. NovaDel's new drug application for ZolpiMist(TM) oral spray to treat insomnia accepted for f iling by the US food and drug administration. [press release] 2008 January 23. www.integratir.com/newsrelease. asp?news=2131020465&ticker=NVD&lang=EN. Accessed 2009-12-6.
8. Zhao P, Bakrenev V, Calderone D, et al. Development of a stability indicating HPLC method for zolpidem tartrate oral spray. AAPS J. 2008;10(S2). Available from: www.aapsj.org.
9. NovaDel Pharma Inc. NovaDel Pharma receives FDA approval of ZolpiMist(TM). [press release] 2008 December 22. http://www.integratir.com/ newsrelease.asp?news=2131022053&ticker=NVD&lang=EN. Accessed 2009 Dec 12.
10. NovaDel Pharma Inc. ZolpiMist FDA approved labeling. 2008.
11. NovaDel Pharma Inc. NovaDel Pharma receives notice of allowance for new US patent covering its oral spray drug delivery technolo. [press release] 2009 November 5. www.integratir.com/newsrelease.asp?news=2131022871&ticker= NVD&lang=EN. Accessed 2009 Dec 12.
12. NovaDel Pharma Inc. NovaDel receives issue notification for new US patent covering its oral spray drug delivery technology. [press release] 2009 December 15. www.integratir.com/newsrelease.asp?news=2131023060&ticker=NVD&lang= EN. Accessed 2009 Dec 15.
13. NovaDel Pharma Inc. NovaDel signs exclusive license and distribution agreement with Hi-Tech Pharmacal Co., Inc.'s subsidiary to commercialize and manufacture ZolpiMist(TM) in the US and Canada. [press release]. 2009 November 16. www.integratir.com/newsrelease.asp?news=2131022899&ticker=NVD&lang= EN. Accessed 2009 Dec 6.
14. Dilone E, Arumugam U, Bergstrom DH, et al. Evaluation of the effect of the route of administration on the human metabolite pattern of zolpidem: ZolpiMist oral spray compared to Ambien tablets. AAPS J. 2008;10(S2). Available from: www.aapsj.org.
15. NovaDel Pharma Inc. NovaDel announces positive data from two studies comparing zolpidem oral spray to Ambien(R) tablets. [press release] 2007 June 5. www.integratir.com/newsrelease.asp?news=2130983049&ticker=NVD&lang=EN. Accessed 2009 Dec 6.
16. NovaDel Pharma Inc. NovaMist technology site. http://www.novadel.com/ technology/index.htm. Accessed 2010 Jan 3.
17. NovaDel Pharma Inc. ZolpiMist website. http://www.novadel.com/pipeline/ zolpimist.htm. Accessed 2010 Jan 3.